Double maintains 3 strategies that include APLS - Apellis Pharmaceuticals, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ROIV | 44.53% | $7.19B | -12.42% | 0.00% |
BEAM | 39.99% | $1.85B | -37.74% | 0.00% |
NTLA | 39.79% | $755.67M | -70.78% | 0.00% |
CRSP | 39.11% | $2.93B | -47.07% | 0.00% |
BARK | 38.84% | $248.38M | +17.36% | 0.00% |
DNLI | 38.27% | $2.00B | -29.07% | 0.00% |
RCKT | 37.10% | $671.77M | -75.23% | 0.00% |
LAB | 35.93% | $447.20M | -55.64% | 0.00% |
IGMS | 35.58% | $73.52M | -86.38% | 0.00% |
ARWR | 35.44% | $1.74B | -52.08% | 0.00% |
ABCL | 35.34% | $661.53M | -49.32% | 0.00% |
ACLX | 35.27% | $3.69B | +6.38% | 0.00% |
CYTK | 35.11% | $4.77B | -43.25% | 0.00% |
IOVA | 34.85% | $1.16B | -74.73% | 0.00% |
RRX | 34.39% | $8.06B | -30.16% | 1.31% |
RYTM | 34.31% | $3.29B | +27.07% | 0.00% |
QTRX | 34.29% | $260.58M | -69.40% | 0.00% |
VSH | 34.18% | $2.16B | -28.21% | 2.94% |
RXRX | 34.05% | $2.13B | -40.76% | 0.00% |
HCAT | 33.85% | $312.44M | -33.48% | 0.00% |
Yahoo
The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
Yahoo
The sNDA application is based on the positive outcomes from the Phase III VALIANT trial at week 26.
Yahoo
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases. The Prescription
Yahoo
In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks involves focusing on companies that demonstrate robust innovation and adaptability in response to evolving market dynamics.
SeekingAlpha
The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.
Yahoo
We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The biotechnology sector is gaining new momentum with better […]
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -35.20% | $416.76M | 1.43% |
VIXY | -25.43% | $195.31M | 0.85% |
TAIL | -18.38% | $87.65M | 0.59% |
USDU | -14.70% | $206.96M | 0.5% |
ULST | -13.33% | $585.14M | 0.2% |
TBIL | -12.72% | $5.39B | 0.15% |
XHLF | -12.50% | $1.06B | 0.03% |
UUP | -10.64% | $325.79M | 0.77% |
TPMN | -9.01% | $33.32M | 0.65% |
USFR | -8.90% | $18.53B | 0.15% |
DBE | -8.43% | $55.52M | 0.77% |
SGOV | -8.09% | $39.98B | 0.09% |
BILZ | -7.45% | $734.41M | 0.14% |
BNO | -7.41% | $99.25M | 1% |
XBIL | -7.41% | $706.15M | 0.15% |
GBIL | -7.07% | $6.30B | 0.12% |
USO | -6.60% | $972.70M | 0.6% |
DBO | -6.52% | $202.41M | 0.77% |
IBTF | -6.47% | $2.22B | 0.07% |
CCOR | -6.03% | $64.12M | 1.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 49.26% | $4.76B | 0.35% |
IBB | 45.87% | $5.61B | 0.45% |
GNOM | 45.65% | $47.13M | 0.5% |
RSPA | 43.91% | $292.67M | 0% |
ARKG | 43.40% | $936.86M | 0.75% |
CPRJ | 43.20% | $48.38M | 0.69% |
IWO | 41.51% | $10.72B | 0.24% |
IWC | 41.01% | $797.08M | 0.6% |
VTWO | 40.11% | $10.92B | 0.07% |
IWM | 40.07% | $62.65B | 0.19% |
XHE | 39.83% | $174.19M | 0.35% |
KAPR | 39.42% | $144.85M | 0.79% |
VBK | 38.93% | $17.32B | 0.07% |
KOMP | 38.92% | $1.95B | 0.2% |
PBW | 38.90% | $213.72M | 0.65% |
PBE | 38.70% | $224.98M | 0.58% |
SCHA | 38.55% | $15.94B | 0.04% |
ISCG | 38.48% | $655.02M | 0.06% |
QQQJ | 38.35% | $592.09M | 0.15% |
VXF | 38.25% | $19.92B | 0.05% |
Current Value
$22.241 Year Return
Current Value
$22.241 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CORN | -0.14% | $52.17M | 0.2% |
ASHR | 0.16% | $2.63B | 0.65% |
CNYA | 0.23% | $218.06M | 0.6% |
BUXX | 0.24% | $234.79M | 0.25% |
AFIF | 0.33% | $135.91M | 1.11% |
CTA | 0.39% | $978.30M | 0.76% |
FTSM | -0.43% | $6.38B | 0.45% |
KBA | 0.44% | $188.42M | 0.56% |
PULS | 0.53% | $11.04B | 0.15% |
BILS | 0.55% | $3.67B | 0.1356% |
AGGH | -0.60% | $317.82M | 0.29% |
VPU | -0.63% | $6.83B | 0.09% |
IBTG | -0.71% | $1.82B | 0.07% |
BCI | 0.87% | $1.45B | 0.26% |
ICLO | -0.88% | $354.74M | 0.2% |
FUTY | -0.92% | $1.70B | 0.084% |
KRBN | 1.13% | $175.08M | 0.85% |
CMDY | 1.19% | $313.96M | 0.28% |
FTGC | 1.26% | $2.52B | 1.02% |
PALL | 1.32% | $376.00M | 0.6% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SITC | -0.04% | $675.30M | +17.17% | 1.08% |
ADM | 0.04% | $23.03B | -23.43% | 4.19% |
ZCMD | 0.09% | $32.02M | -17.53% | 0.00% |
FMC | -0.20% | $5.32B | -29.05% | 5.92% |
KO | 0.20% | $306.97B | +19.22% | 2.66% |
COKE | -0.20% | $12.20B | +72.27% | 0.44% |
LNT | -0.24% | $16.55B | +30.41% | 2.98% |
UNH | 0.28% | $478.58B | +13.80% | 1.56% |
SAVA | -0.30% | $67.15M | -93.25% | 0.00% |
FLNG | 0.31% | $1.21B | -15.10% | 13.79% |
CVS | 0.31% | $85.82B | -8.75% | 3.91% |
AWK | 0.32% | $28.51B | +22.92% | 1.99% |
AGS | 0.36% | $500.47M | +38.15% | 0.00% |
SYPR | 0.38% | $37.52M | -3.55% | 0.00% |
PHG | -0.46% | $22.98B | +25.80% | 0.00% |
KNOP | -0.46% | $260.66M | +43.40% | 1.46% |
OCFT | 0.46% | $248.36M | +201.34% | 0.00% |
INTU | -0.49% | $173.58B | -0.34% | 0.64% |
UBS | 0.50% | $96.67B | -2.18% | 1.23% |
FNKO | 0.51% | $368.05M | +12.52% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ED | -15.06% | $38.69B | +21.90% | 2.95% |
FATBB | -14.05% | $56.94M | -23.78% | 14.95% |
MO | -13.98% | $96.57B | +35.61% | 6.83% |
CBOE | -13.33% | $23.50B | +25.53% | 1.05% |
K | -12.27% | $28.46B | +45.70% | 2.75% |
AEP | -11.78% | $57.54B | +27.77% | 3.31% |
EXC | -11.28% | $46.41B | +23.54% | 3.25% |
MCK | -11.26% | $86.92B | +28.41% | 0.38% |
WEC | -10.74% | $34.37B | +34.01% | 3.09% |
CORT | -9.84% | $8.84B | +226.74% | 0.00% |
LITB | -9.60% | $41.93M | -46.48% | 0.00% |
RPRX | -9.59% | $13.55B | +8.61% | 2.68% |
TCTM | -8.66% | $3.92M | -82.22% | 0.00% |
CHRW | -8.50% | $12.16B | +43.26% | 2.56% |
CHD | -7.88% | $26.66B | +5.00% | 1.03% |
CEG | -7.81% | $67.19B | +12.72% | 0.74% |
CMS | -7.75% | $22.33B | +25.86% | 2.76% |
T | -7.75% | $201.99B | +59.80% | 3.85% |
HUSA | -7.74% | $11.76M | -47.55% | 0.00% |
LMT | -7.69% | $106.60B | +1.11% | 2.84% |